Skip To Main Content
Patrick Tshilab Kabwit on Muck Rack

Patrick Tshilab Kabwit

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Patrick Tshilab

Contact Patrick Tshilab, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Sevuparin in children with severe malaria: a phase I safety and dose-finding trial

|
By Jonathan Gwasupika, Roisin Connon, Sam Miti, Nchafatso G. Obonyo, Diana M. Gibb, Thomas Williams, Nicholas Day, Arjen M. Dondorp, A. Sarah Walker, Elizabeth George, Kathryn Maitland, Mike Chaponda, Patrick Tshilab Kabwit
| Nature Verified
Abstract Mortality rates for African children with severe malaria remain high. Sevuparin, a heparin-like compound, as an adjunctive treatment, may improve outcomes due to its effects on Plasmodium falciparum-infected erythrocytes. A Phase I dose-finding trial in Kenyan and Zambian children with severe malaria aimed to identify the maximum tolerated dose (MTD) of sevuparin, given as three infusions (at 0, 8 and 16 h post-enrolment) using the continual reassessment method (ISRCTN32271864).
Open in Who Shared Issue with article?
See all 1 articles